You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) - including polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PM) - are clonal stem cell disorders characterized by acquired activating mutations which result in an excessive production of red blood cells, platelets, and neutrophils. Recent advances in the understanding of the molecular biology and genomics of MPNs have led to the development of novel targeted treatment approaches; however, the high rate of life-threatening vascular events and the high risk of disease progression with myelofibrotic and leukemic transformation continue to present challenges in the management of MPNs. Thereby, there remains a need for novel treatment strategies. Recently, research has revealed a role for clonal hematopoiesis, driver mutations and inflammation in thrombosis risk, which may provide a basis for novel thrombosis-prevention strategies.
Presents the broad outline of NIH organizational structure, theprofessional staff, and their scientific and technical publications covering work done at NIH.
None
Each issue lists papers published during the preceding year.
The Proceedings of the National Academy of Sciences (PNAS) publishes research reports, commentaries, reviews, colloquium papers, and actions of the Academy. PNAS is a multidisciplinary journal that covers the biological, physical, and social sciences.